These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 31828474)
1. Frequency and clinical features of treatment-refractory myasthenia gravis. Rath J; Brunner I; Tomschik M; Zulehner G; Hilger E; Krenn M; Paul A; Cetin H; Zimprich F J Neurol; 2020 Apr; 267(4):1004-1011. PubMed ID: 31828474 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R; Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163 [TBL] [Abstract][Full Text] [Related]
10. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Kupersmith MJ; Latkany R; Homel P Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710 [TBL] [Abstract][Full Text] [Related]
11. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up. Triantafyllou NI; Grapsa EI; Kararizou E; Psimenou E; Lagguranis A; Dimopoulos A Ther Apher Dial; 2009 Jun; 13(3):174-8. PubMed ID: 19527462 [TBL] [Abstract][Full Text] [Related]
12. Employment in refractory myasthenia gravis: A Myasthenia Gravis Foundation of America Registry analysis. Harris L; Aban IB; Xin H; Cutter G Muscle Nerve; 2019 Dec; 60(6):700-706. PubMed ID: 31478207 [TBL] [Abstract][Full Text] [Related]